Grifols, S.A. (NASDAQ:GRFS) Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. lessened its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 234,565 shares of the biotechnology company’s stock after selling 7,247 shares during the period. Hantz Financial Services Inc.’s holdings in Grifols were worth $1,745,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its stake in Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after buying an additional 1,181,959 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Grifols in the 2nd quarter valued at approximately $359,000. Stifel Financial Corp acquired a new stake in Grifols in the 3rd quarter worth approximately $1,043,000. Helikon Investments Ltd purchased a new stake in Grifols during the 4th quarter worth approximately $580,000. Finally, GAMMA Investing LLC increased its stake in Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,527 shares in the last quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $6.91 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 52-week low of $5.30 and a 52-week high of $9.96. The business has a 50-day moving average price of $7.53 and a 200-day moving average price of $8.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.